Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer

• Verfasst von: Brahmer, Julie [VerfasserIn]
• Verfasst von: Steins, Martin [VerfasserIn]
• Titel: Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer
• Verf.angabe: Julie Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried E.E. Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina C. Garassino, Joachim G. Aerts, Manuel Domine, Luis Paz-Ares, Martin Reck, Christine Baudelet, Christopher T. Harbison, Brian Lestini, David R. Spigel
• Umfang: 13 S.
• Fussnoten: Gesehen am 22.03.2017
• Titel Quelle: Enthalten in: The New England journal of medicine
• Jahr Quelle: 2015
• Band/Heft Quelle: 373(2015), 2, S. 123-135
• ISSN Quelle: 1533-4406
• DOI: doi:10.1056/NEJMoa1504627
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1555760031

Abstract

Squamous-cell carcinoma represents approximately 30% of all cases of non-small-cell lung cancer (NSCLC).1 Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.2-4 Most new agents for the treatment of NSCLC are not indicated for this subtype because of their toxicity or lack of efficacy or because their activity is limited to tumors with specific genetic alterations that are rarely found in squamous-cell NSCLC.5-7 Furthermore, no single-agent therapy has resulted in better survival than that seen with docetaxel. The programmed death 1 (PD-1) . . .